14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Sep 28, 2023 $150.78 $152.48 $146.31 $151.69 408 965
Sep 27, 2023 $149.45 $153.52 $149.20 $151.48 286 850
Sep 26, 2023 $143.75 $153.05 $143.75 $148.95 368 316
Sep 25, 2023 $153.56 $154.03 $149.37 $150.94 246 103
Sep 22, 2023 $161.22 $161.72 $151.42 $153.34 366 901
Sep 21, 2023 $159.40 $162.16 $157.66 $159.51 302 481
Sep 20, 2023 $169.19 $170.56 $159.39 $161.42 440 844
Sep 19, 2023 $161.62 $170.27 $161.62 $169.35 305 542
Sep 18, 2023 $174.24 $176.56 $163.45 $163.58 342 834
Sep 15, 2023 $175.78 $182.00 $172.80 $175.89 789 837
Sep 14, 2023 $192.58 $192.58 $174.78 $175.34 687 464
Sep 13, 2023 $188.50 $193.34 $178.30 $190.43 1 326 756
Sep 12, 2023 $184.82 $186.69 $174.86 $176.87 433 217
Sep 11, 2023 $185.20 $187.66 $175.80 $184.99 720 641
Sep 08, 2023 $191.38 $200.62 $190.80 $196.58 262 690
Sep 07, 2023 $184.42 $193.07 $184.42 $191.03 262 867
Sep 06, 2023 $184.50 $187.52 $182.99 $185.38 123 827
Sep 05, 2023 $184.51 $189.61 $184.28 $184.50 302 004
Sep 01, 2023 $181.25 $185.53 $179.52 $185.14 133 990
Aug 31, 2023 $178.80 $181.18 $176.32 $180.00 153 397
Aug 30, 2023 $179.75 $181.73 $177.30 $178.09 113 886
Aug 29, 2023 $180.84 $182.51 $178.23 $179.49 108 948
Aug 28, 2023 $179.60 $180.87 $177.91 $180.83 142 316
Aug 25, 2023 $177.62 $181.21 $175.40 $179.32 170 556
Aug 24, 2023 $179.74 $180.02 $175.33 $177.27 162 742
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT